OM:SUS

Stock Analysis Report

Surgical Science Sweden

Executive Summary

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Surgical Science Sweden's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.0%

SUS

-0.5%

SE Medical Equipment

1.9%

SE Market


1 Year Return

352.0%

SUS

34.2%

SE Medical Equipment

9.6%

SE Market

Return vs Industry: SUS exceeded the Swedish Medical Equipment industry which returned 34.2% over the past year.

Return vs Market: SUS exceeded the Swedish Market which returned 9.6% over the past year.


Shareholder returns

SUSIndustryMarket
7 Day8.0%-0.5%1.9%
30 Day27.9%-0.05%-0.3%
90 Day31.9%-5.3%0.7%
1 Year352.0%352.0%35.6%34.2%14.3%9.6%
3 Yearn/a47.0%29.5%31.5%11.9%
5 Yearn/a70.1%42.0%66.2%30.8%

Price Volatility Vs. Market

How volatile is Surgical Science Sweden's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Surgical Science Sweden undervalued compared to its fair value and its price relative to the market?

44.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: SUS (SEK339) is trading below our estimate of fair value (SEK611.33)

Significantly Undervalued: SUS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SUS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SUS is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SUS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SUS is overvalued based on its PB Ratio (22.8x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Surgical Science Sweden forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

80.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SUS's revenue (41.6% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: SUS's revenue (41.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: SUS's Return on Equity is forecast to be low in 3 years time (13.4%).


Next Steps

Past Performance

How has Surgical Science Sweden performed over the past 5 years?

-38.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SUS is unprofitable, and losses have increased over the past 5 years at a rate of -38.9% per year.

Accelerating Growth: Unable to compare SUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SUS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: SUS has a negative Return on Equity (-6.78%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SUS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SUS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Surgical Science Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: SUS's short term assets (SEK57.6M) exceeds its short term liabilities (SEK19.6M)

Long Term Liabilities: SUS's short term assets (57.6M) exceeds its long term liabilities (7.4M)


Debt to Equity History and Analysis

Debt Level: SUS is debt free.

Reducing Debt: SUS had no debt 5 years ago.


Balance Sheet

Inventory Level: SUS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SUS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SUS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SUS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 39.8% per year.


Next Steps

Dividend

What is Surgical Science Sweden's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SUS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SUS's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Surgical Science Sweden's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average board tenure


CEO

Gisli Hennermark 0

4.8yrs

Tenure

0

Mr. Gisli Hennermark serves as Chief Executive Officer of Surgical Science Sweden AB (publ) since 2015. He received MSc from Stockholm School of Economics and Cornell University. He worked previously as a  ...


Board Age and Tenure

2.8yrs

Average Tenure

64yo

Average Age

Experienced Board: SUS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Anders Larsson

    Co-Founder & CTO

    • Tenure: 0yrs
  • Gisli Hennermark

    Chief Executive Officer

    • Tenure: 4.8yrs
  • Anna Ahlberg (49yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
  • Jan Pedersen (54yo)

    Director of Global Accounts

    • Tenure: 0yrs
  • Anders Melander

    Director of Global Sales

    • Tenure: 0yrs

Board Members

  • Roland Bengtsson (64yo)

    Chairman of the Board

    • Tenure: 2.8yrs
  • Jan Bengtsson (75yo)

    Director

    • Tenure: 14.8yrs
  • Thomas Eklund (52yo)

    Director

    • Tenure: 2.8yrs
  • Nils Sellbom (60yo)

    Director

    • Tenure: 7.8yrs
  • Tommy Forsell (66yo)

    Director

    • Tenure: 0.8yrs

Company Information

Surgical Science Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Surgical Science Sweden AB (publ)
  • Ticker: SUS
  • Exchange: OM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr2.280b
  • Shares outstanding: 6.72m
  • Website: https://www.surgicalscience.com

Location

  • Surgical Science Sweden AB (publ)
  • Drakegatan 7 A, 3 tr.
  • Gothenburg
  • Västra Götaland County
  • 412 50
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SUSOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017

Biography

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 22:07
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.